Lisata Therapeutics Inc (LTS:0HS8)
$ 3.255 0 (0%) Market Cap: 28.95 Mil Enterprise Value: -14.23 Mil PE Ratio: 0 PB Ratio: 0.67 GF Score: 37/100

Q4 2020 Caladrius Biosciences Inc Earnings Call Transcript

Feb 25, 2021 / 09:30PM GMT
Release Date Price: $29.85 (-2.21%)
Operator

Welcome to the Caladrius Biosciences Fourth Quarter and Year-End 2020 Financial Results and Business Update Conference Call. (Operator Instructions)

As a reminder, this call is being recorded today, Thursday, February 25, 2021.

I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

John D. Menditto
Caladrius Biosciences, Inc. - VP of IR & Corporate Communications

Thank you, operator, and good afternoon, everyone. Welcome to Caladrius' Fourth Quarter and Year-End 2020 Conference Call to discuss our financial results and provide a business update. Joining me today is Dr. David Mazzo, the company's President and Chief Executive Officer.

Earlier today, we issued a press release announcing our fourth quarter and year-end 2020 financial results, which is available under the Investors section of our company website. If you have not received this news release or if you'd like to be added to the company's e-mail distribution list, please e

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot